Literature DB >> 29882724

Celastrol as a pentacyclic triterpenoid with chemopreventive properties.

Priya Yadav1, Vishal Jaswal2, Ajay Sharma2, Dharambir Kashyap3, Hardeep S Tuli1, Vivek K Garg4, Shonkor K Das5, R Srinivas6.   

Abstract

Celastrol is a highly investigated anticancer moiety. It is a pentacyclic triterpenoid, isolated several decades ago with promising role in chemoprevention. Celastrol has been found to target multiple proinflammatory, angiogenic and metastatic proteins. Inhibition of these targets results in significant reduction of cancer growth, survival and metastasis. This review summarizes the varied molecular targets of celastrol along with insight into the various recently published clinical, preclinical and industrial patents (2011-2017).

Entities:  

Keywords:  anti-inflammation; antiangiogenesis; anticancer; antimetastasis; antioxidant; celastrol; patents

Mesh：

Substances：

Year:  2018        PMID： 29882724     DOI： 10.4155/ppa-2017-0035

Source DB:  PubMed          Journal:  Pharm Pat Anal        ISSN： 2046-8954


  9 in total

Review 1.  Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.

Authors:  Hardeep Singh Tuli; Vivek Kumar Garg; Ajay Kumar; Diwakar Aggarwal; Uttpal Anand; Nidarshana Chaturvedi Parashar; Adesh K Saini; Ranjan K Mohapatra; Kuldeep Dhama; Manoj Kumar; Tejveer Singh; Jagjit Kaur; Katrin Sak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-10       Impact factor: 3.195

2.  Prooxidative Activity of Celastrol Induces Apoptosis, DNA Damage, and Cell Cycle Arrest in Drug-Resistant Human Colon Cancer Cells.

Authors:  Helena Moreira; Anna Szyjka; Kamila Paliszkiewicz; Ewa Barg
Journal:  Oxid Med Cell Longev       Date:  2019-08-14       Impact factor: 6.543

Review 3.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

Review 4.  Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes as Therapeutic Agents.

Authors:  Codruţa Şoica; Mirela Voicu; Roxana Ghiulai; Cristina Dehelean; Roxana Racoviceanu; Cristina Trandafirescu; Oana-Janina Roșca; Gabriela Nistor; Marius Mioc; Alexandra Mioc
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-21       Impact factor: 5.555

5.  Identifying the Effect of Celastrol Against Ovarian Cancer With Network Pharmacology and In Vitro Experiments.

Authors:  Xuan Wang; Qiong Liu; Sisi Wu; Nana Xu; Hua Li; Aihua Feng
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

6.  Design, Synthesis, and Cytotoxic Analysis of Novel Hederagenin⁻Pyrazine Derivatives Based on Partial Least Squares Discriminant Analysis.

Authors:  Kang Fang; Xiao-Hua Zhang; Yao-Tian Han; Gao-Rong Wu; De-Sheng Cai; Nan-Nan Xue; Wen-Bo Guo; Yu-Qin Yang; Meng Chen; Xin-Yu Zhang; Hui Wang; Tao Ma; Peng-Long Wang; Hai-Min Lei
Journal:  Int J Mol Sci       Date:  2018-09-30       Impact factor: 5.923

7.  Hyaluronic acid-functionalized bilosomes for targeted delivery of tripterine to inflamed area with enhancive therapy on arthritis.

Authors:  Hailing Yang; Zhenjie Liu; Yonglong Song; Changjiang Hu
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

8.  Celastrol and Melatonin Modify SIRT1, SIRT6 and SIRT7 Gene Expression and Improve the Response of Human Granulosa-Lutein Cells to Oxidative Stress.

Authors:  Rita Martín-Ramírez; Rebeca González-Fernández; Jairo Hernández; Pablo Martín-Vasallo; Angela Palumbo; Julio Ávila
Journal:  Antioxidants (Basel)       Date:  2021-11-24

9.  Thymoquinone-Enriched Naringenin-Loaded Nanostructured Lipid Carrier for Brain Delivery via Nasal Route: In Vitro Prospect and In Vivo Therapeutic Efficacy for the Treatment of Depression.

Authors:  Farheen Fatima Qizilbash; Muhammad Usama Ashhar; Ameeduzzafar Zafar; Zufika Qamar; Javed Ali; Sanjula Baboota; Mohammed M Ghoneim; Sultan Alshehri; Asgar Ali
Journal:  Pharmaceutics       Date:  2022-03-16       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.